Virpax Pharma rises as pain medication shows promise in animal study

Virpax Pharmaceuticals

10/07/2024 13:12

** Shares of drug developer Virpax Pharmaceuticals  VRPX.O 
rise 79.3% to $2.07 premarket
    ** Co announces positive results from an animal study
testing its non-addictive pain medication, probudur
    ** Co says the treatment was injected into 4 domestic pigs
at a dose of 30 mg/kg and was well-tolerated by all of the pigs 
    ** The study was designed to determine how the body reacts
to the treatment after it is administered and to ascertain any
adverse effects on the pigs
    ** Probudur is being developed to significantly reduce or
eliminate the need for opioids after surgery in approved
indications - VRPX 
    ** The experimental treatment is injected at a wound site to
provide both immediate and extended pain relief  
    ** Up to last close, stock down 63.8% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))